Peptides for nucleic acid delivery

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 172-182

  Lehto, Taavi ^a,b   Ezzat, Kariem ^a   Wood, Matthew J A ^c   EL Andaloussi, Samir ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antisense oligonucleotides; Cell penetrating peptides; Delivery peptides; Nanoparticles; Nucleic acid delivery; Oligonucleotides; siRNA; Splice switching oligonucleotides

Indexed keywords

BIOCHEMISTRY; BIOMOLECULES; CELL CULTURE; GENE THERAPY; NANOPARTICLES; NUCLEIC ACIDS; OLIGONUCLEOTIDES; PEPTIDES;

ANTISENSE OLIGONUCLEOTIDES; CELL PENETRATING PEPTIDES (CPPS); CELL-PENETRATING PEPTIDE; DRUG DELIVERY SYSTEM; NANOPARTICLE FORMATION; NUCLEIC ACID DELIVERIES; SIRNA; THERAPEUTIC COMPOUNDS;

ANIMAL CELL CULTURE;

CELL PENETRATING PEPTIDE; DNA; DRUG CARRIER; NANOCARRIER; NUCLEIC ACID; OLIGODEOXYNUCLEOTIDE; SMALL INTERFERING RNA; NANOPARTICLE; OLIGONUCLEOTIDE;

CELL CULTURE; COVALENT BOND; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; PROCEDURES;

ANIMALS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NUCLEIC ACIDS; OLIGONUCLEOTIDES;

EID: 84994885261     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.06.008     Document Type: Review

References (123)

1. [1] Kole, R., Krainer, A.R., Altman, S., RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11 (2012), 125–140, 10.1038/nrd3625.
2. [2] Muntoni, F., Wood, M.J.A., Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov. 10 (2011), 621–637, 10.1038/nrd3459.
3. [3] Bennett, C.F., Swayze, E.E., RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50 (2010), 259–293, 10.1146/annurev.pharmtox.010909.105654.
4. [4] Watts, J.K., Corey, D.R., Silencing disease genes in the laboratory and the clinic. J. Pathol. 226 (2012), 365–379, 10.1002/path.2993.
5. [5] Bader, A.G., Brown, D., Winkler, M., The promise of microRNA replacement therapy. Cancer Res. 70 (2010), 7027–7030, 10.1158/0008-5472.CAN-10-2010.
6. [6] Lundin, K.E., Gissberg, O., Smith, C.I.E., Oligonucleotide therapies: the past and the present. Hum. Gene Ther. 26 (2015), 475–485, 10.1089/hum.2015.070.
7. [7] Wright, A.V., Nuñez, J.K., Doudna, J.A., Biology and applications of CRISPR systems: harnessing nature's toolbox for genome engineering. Cell 164 (2016), 29–44, 10.1016/j.cell.2015.12.035.
8. [8] Cox, D.B.T., Platt, R.J., Zhang, F., Therapeutic genome editing: prospects and challenges. Nat. Med. 21 (2015), 121–131, 10.1038/nm.3793.
9. [9] Chien, K.R., Zangi, L., Lui, K.O., Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine. Cold Spring Harb. Perspect. Med., 5, 2015, a014035, 10.1101/cshperspect.a014035.
10. [10] Geary, R.S., Norris, D., Yu, R., Bennett, C.F., Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev., 2015, 10.1016/j.addr.2015.01.008.
11. [11] Juliano, R.l., Ming, X., Carver, K., Laing, B., Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther. 24 (2014), 101–113, 10.1089/nat.2013.0463.
12. [12] Naldini, L., Gene therapy returns to centre stage. Nature 526 (2015), 351–360, 10.1038/nature15818.
13. [13] Pack, D.W., Hoffman, A.S., Pun, S., Stayton, P.S., Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 4 (2005), 581–593.
14. [14] Lächelt, U., Wagner, E., Nucleic acid therapeutics using polyplexes: a journey of 50 years (and beyond). Chem. Rev. 115 (2015), 11043–11078, 10.1021/cr5006793.
15. [15] Lehto, T., Wagner, E., Sequence-defined polymers for the delivery of oligonucleotides. Nanomedicine 9 (2014), 2843–2859, 10.2217/nnm.14.166.
16. [16] Pooga, M., Langel, Ü., Classes of cell-penetrating peptides. Methods Mol. Biol. Clifton N.J. 1324 (2015), 3–28, 10.1007/978-1-4939-2806-4_1.
17. [17] Heitz, F., Morris, M.C., Divita, G., Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 157 (2009), 195–206, 10.1111/j.1476-5381.2009.00057.x.
18. [18] Futaki, S., Hirose, H., Nakase, I., Arginine-rich peptides: methods of translocation through biological membranes. Curr. Pharm. Des. 19 (2013), 2863–2868.
19. [19] Lehto, T., Kurrikoff, K., Langel, Ü., Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin. Drug Deliv. 9 (2012), 823–836, 10.1517/17425247.2012.689285.
20. [20] El Andaloussi, S.A., Hammond, S.M., Mäger, I., Wood, M.J.A., Use of cell-penetrating-peptides in oligonucleotide splice switching therapy. Curr. Gene Ther. 12 (2012), 161–178.
21. [21] Boisguérin, P., Deshayes, S., Gait, M.J., O'Donovan, L., Godfrey, C., Betts, C.A., Wood, M.J.A., Lebleu, B., Delivery of therapeutic oligonucleotides with cell penetrating peptides. Adv. Drug Deliv. Rev. 87 (2015), 52–67, 10.1016/j.addr.2015.02.008.
22. [22] Presente, A., Dowdy, S.F., PTD/CPP peptide-mediated delivery of siRNAs. Curr. Pharm. Des. 19 (2013), 2943–2947.
23. [23] Hansen, M., Kilk, K., Langel, U., Predicting cell-penetrating peptides. Adv. Drug Deliv. Rev. 60 (2008), 572–579, 10.1016/j.addr.2007.09.003.
24. [24] Brock, R., The uptake of arginine-rich cell-penetrating peptides: putting the puzzle together. Bioconjug. Chem. 25 (2014), 863–868, 10.1021/bc500017t.
25. [25] Margus, H., Padari, K., Pooga, M., Insights into cell entry and intracellular trafficking of peptide and protein drugs provided by electron microscopy. Adv. Drug Deliv. Rev. 65 (2013), 1031–1038, 10.1016/j.addr.2013.04.013.
26. [26] Cleal, K., He, L., Watson, P.D., Jones, A.T., Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles. Curr. Pharm. Des. 19 (2013), 2878–2894.
27. [27] El-Sayed, A., Harashima, H., Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis. Mol. Ther. 21 (2013), 1118–1130, 10.1038/mt.2013.54.
28. [28] Rydström, A., Deshayes, S., Konate, K., Crombez, L., Padari, K., Boukhaddaoui, H., Aldrian, G., Pooga, M., Divita, G., Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PLoS One, 6, 2011, e25924, 10.1371/journal.pone.0025924.
29. [29] El-Sayed, A., Futaki, S., Harashima, H., Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 11 (2009), 13–22, 10.1208/s12248-008-9071-2.
30. [30] Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., Buganim, Y., Schroeder, A., Langer, R., Anderson, D.G., Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31 (2013), 653–658, 10.1038/nbt.2614.
31. [31] Järver, P., O'Donovan, L., Gait, M.J., A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther. 24 (2013), 37–47, 10.1089/nat.2013.0454.
32. [32] Jarver, P., Coursindel, T., Andaloussi, S.E., Godfrey, C., Wood, M.J., Gait, M.J., Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol. Ther.–Nucleic Acids, 1, 2012, e27, 10.1038/mtna.2012.18.
33. [33] Deshayes, S., Morris, M., Heitz, F., Divita, G., Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv. Drug Deliv. Rev. 60 (2008), 537–547, 10.1016/j.addr.2007.09.005.
34. [34] Lehto, T., Ezzat, K., Langel, U., Peptide nanoparticles for oligonucleotide delivery. Prog. Mol. Biol. Transl. Sci. 104 (2011), 397–426, 10.1016/B978-0-12-416020-0.00010-3.
35. [35] Nielsen, P.E., Egholm, M., Berg, R.H., Buchardt, O., Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254 (1991), 1497–1500, 10.1126/science.1962210.
36. [36] Sazani, P., Gemignani, F., Kang, S.-H., Maier, M.A., Manoharan, M., Persmark, M., Bortner, D., Kole, R., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20 (2002), 1228–1233, 10.1038/nbt759.
37. [37] Bendifallah, N., Rasmussen, F.W., Zachar, V., Ebbesen, P., Nielsen, P.E., Koppelhus, U., Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug. Chem. 17 (2006), 750–758, 10.1021/bc050283q.
38. [38] Lundin, P., Johansson, H., Guterstam, P., Holm, T., Hansen, M., Langel, U., Andaloussi, S.E.L., Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug. Chem. 19 (2008), 2535–2542, 10.1021/bc800212j.
39. [39] El Andaloussi, S., Guterstam, P., Langel, U., Assessing the delivery efficacy and internalization route of cell-penetrating peptides. Nat. Protoc. 2 (2007), 2043–2047, 10.1038/nprot.2007.302.
40. [40] Boffa, L.C., Cutrona, G., Cilli, M., Matis, S., Damonte, G., Mariani, M.R., Millo, E., Moroni, M., Roncella, S., Fedeli, F., Ferrarini, M., Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. Cancer Gene Ther. 14 (2007), 220–226, 10.1038/sj.cgt.7701002.
41. [41] Rogers, F.A., Lin, S.S., Hegan, D.C., Krause, D.S., Glazer, P.M., Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate. Mol. Ther. J. Am. Soc. Gene Ther. 20 (2012), 109–118, 10.1038/mt.2011.163.
42. [42] Brognara, E., Fabbri, E., Aimi, F., Manicardi, A., Bianchi, N., Finotti, A., Breveglieri, G., Borgatti, M., Corradini, R., Marchelli, R., Gambari, R., Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int. J. Oncol. 41 (2012), 2119–2127, 10.3892/ijo.2012.1632.
43. [43] Fabani, M.M., Abreu-Goodger, C., Williams, D., Lyons, P.A., Torres, A.G., Smith, K.G.C., Enright, A.J., Gait, M.J., Vigorito, E., Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res. 38 (2010), 4466–4475, 10.1093/nar/gkq160.
44. [44] Abes, S., Moulton, H.M., Clair, P., Prevot, P., Youngblood, D.S., Wu, R.P., Iversen, P.L., Lebleu, B., Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J. Control. Release 116 (2006), 304–313, 10.1016/j.jconrel.2006.09.011.
45. [45] Abes, R., Moulton, H.M., Clair, P., Yang, S.T., Abes, S., Melikov, K., Prevot, P., Youngblood, D.S., Iversen, P.L., Chernomordik, L.V., Lebleu, B., Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure–activity studies. Nucleic Acids Res. 36 (2008), 6343–6354, 10.1093/nar/gkn541.
46. [46] Finsterer, J., Stöllberger, C., The heart in human dystrophinopathies. Cardiology 99 (2003), 1–19 (doi:68446).
47. [47] van Westering, T.L.E., Betts, C.A., Wood, M.J.A., Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. Mol. Basel Switz. 20 (2015), 8823–8855, 10.3390/molecules20058823.
48. [48] Douglas, A.G.L., Wood, M.J.A., Splicing therapy for neuromuscular disease. Mol. Cell. Neurosci. 56 (2013), 169–185, 10.1016/j.mcn.2013.04.005.
49. [49] Koo, T., Wood, M.J., Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Hum. Gene Ther. 24 (2013), 479–488, 10.1089/hum.2012.234.
50. [50] Yin, H., Moulton, H.M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P., Wood, M.J., Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet. 17 (2008), 3909–3918, 10.1093/hmg/ddn293.
51. [51] Wu, B., Moulton, H.M., Iversen, P.L., Jiang, J., Li, J., Li, J., Spurney, C.F., Sali, A., Guerron, A.D., Nagaraju, K., Doran, T., Lu, P., Xiao, X., Lu, Q.L., Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 14814–14819, 10.1073/pnas.0805676105.
52. [52] Yin, H., Moulton, H.M., Betts, C., Seow, Y., Boutilier, J., Iverson, P.L., Wood, M.J.A., A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum. Mol. Genet. 18 (2009), 4405–4414, 10.1093/hmg/ddp395.
53. [53] Yin, H., Saleh, A.F., Betts, C., Camelliti, P., Seow, Y., Ashraf, S., Arzumanov, A., Hammond, S., Merritt, T., Gait, M.J., Wood, M.J., Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther. 19 (2011), 1295–1303, 10.1038/mt.2011.79.
54. [54] Betts, C., Saleh, A.F., Arzumanov, A.A., Hammond, S.M., Godfrey, C., Coursindel, T., Gait, M.J., Wood, M.J., Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther.–Nucleic Acids, 1, 2012, e38, 10.1038/mtna.2012.30.
55. [55] Betts, C.A., Saleh, A.F., Carr, C.A., Hammond, S.M., Coenen-Stass, A.M.L., Godfrey, C., McClorey, G., Varela, M.A., Roberts, T.C., Clarke, K., Gait, M.J., Wood, M.J.A., Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Sci. Rep., 5, 2015, 10.1038/srep08986.
56. [56] Godfrey, C., Muses, S., McClorey, G., Wells, K.E., Coursindel, T., Terry, R.L., Betts, C., Hammond, S., O'Donovan, L., Hildyard, J., Andaloussi, S.E., Gait, M.J., Wood, M.J., Wells, D.J., How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum. Mol. Genet. 24 (2015), 4225–4237, 10.1093/hmg/ddv155.
57. [57] Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S.E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T., Amthor, H., Bühr, C., Schürch, S., Wood, M.J.A., Davies, K.E., Vaillend, C., Leumann, C., Garcia, L., Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med., 2015, 10.1038/nm.3765 (advance online publication).
58. [58] Leger, A.J., Mosquea, L.M., Clayton, N.P., Wu, I.-H., Weeden, T., Nelson, C.A., Phillips, L., Roberts, E., Piepenhagen, P.A., Cheng, S.H., Wentworth, B.M., Systemic delivery of a peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy. Nucleic Acid Ther. 23 (2013), 109–117, 10.1089/nat.2012.0404.
59. [59] Bestas, B., Moreno, P.M.D., Blomberg, K.E.M., Mohammad, D.K., Saleh, A.F., Sutlu, T., Nordin, J.Z., Guterstam, P., Gustafsson, M.O., Kharazi, S., Piątosa, B., Roberts, T.C., Behlke, M.A., Wood, M.J.A., Gait, M.J., Lundin, K.E., El Andaloussi, S., Månsson, R., Berglöf, A., Wengel, J., Smith, C.I.E., Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J. Clin. Invest. 124 (2014), 4067–4081, 10.1172/JCI76175.
60. [60] Lai, S.-H., Stein, D.A., Guerrero-Plata, A., Liao, S.-L., Ivanciuc, T., Hong, C., Iversen, P.L., Casola, A., Garofalo, R.P., Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol. Ther. J. Am. Soc. Gene Ther. 16 (2008), 1120–1128, 10.1038/mt.2008.81.
61. [61] Opriessnig, T., Patel, D., Wang, R., Halbur, P.G., Meng, X.-J., Stein, D.A., Zhang, Y.-J., Inhibition of porcine reproductive and respiratory syndrome virus infection in piglets by a peptide-conjugated morpholino oligomer. Antivir. Res. 91 (2011), 36–42, 10.1016/j.antiviral.2011.04.012.
62. [62] Burrer, R., Neuman, B.W., Ting, J.P.C., Stein, D.A., Moulton, H.M., Iversen, P.L., Kuhn, P., Buchmeier, M.J., Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J. Virol. 81 (2007), 5637–5648, 10.1128/JVI.02360-06.
63. [63] Stein, D.A., Huang, C.Y.-H., Silengo, S., Amantana, A., Crumley, S., Blouch, R.E., Iversen, P.L., Kinney, R.M., Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J. Antimicrob. Chemother. 62 (2008), 555–565, 10.1093/jac/dkn221.
64. [64] Deas, T.S., Bennett, C.J., Jones, S.A., Tilgner, M., Ren, P., Behr, M.J., Stein, D.A., Iversen, P.L., Kramer, L.D., Bernard, K.A., Shi, P.-Y., In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob. Agents Chemother. 51 (2007), 2470–2482, 10.1128/AAC.00069-07.
65. [65] Tilley, L.D., Mellbye, B.L., Puckett, S.E., Iversen, P.L., Geller, B.L., Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose–response in mice infected with Escherichia coli. J. Antimicrob. Chemother. 59 (2007), 66–73, 10.1093/jac/dkl444.
66. [66] Wesolowski, D., Tae, H.S., Gandotra, N., Llopis, P., Shen, N., Altman, S., Basic peptide-morpholino oligomer conjugate that is very effective in killing bacteria by gene-specific and nonspecific modes. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 16582–16587, 10.1073/pnas.1112561108.
67. [67] Panchal, R.G., Geller, B.L., Mellbye, B., Lane, D., Iversen, P.L., Bavari, S., Peptide conjugated phosphorodiamidate morpholino oligomers increase survival of mice challenged with Ames Bacillus anthracis. Nucleic Acid Ther. 22 (2012), 316–322, 10.1089/nat.2012.0362.
68. [68] Geller, B.L., Marshall-Batty, K., Schnell, F.J., McKnight, M.M., Iversen, P.L., Greenberg, D.E., Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo. J. Infect. Dis. 208 (2013), 1553–1560, 10.1093/infdis/jit460.
69. [69] Morris, M.C., Vidal, P., Chaloin, L., Heitz, F., Divita, G., A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25 (1997), 2730–2736.
70. [70] Wyman, T.B., Nicol, F., Zelphati, O., Scaria, P.V., Plank, C., Szoka, F.C., Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry (Mosc) 36 (1997), 3008–3017, 10.1021/bi9618474.
71. [71] Morris, M.C., Chaloin, L., Méry, J., Heitz, F., Divita, G., A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res. 27 (1999), 3510–3517.
72. [72] Crombez, L., Morris, M.C., Dufort, S., Aldrian-Herrada, G., Nguyen, Q., Mc Master, G., Coll, J.L., Heitz, F., Divita, G., Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res. 37 (2009), 4559–4569, 10.1093/nar/gkp451.
73. [73] Crombez, L., Aldrian-Herrada, G., Konate, K., Nguyen, Q.N., McMaster, G.K., Brasseur, R., Heitz, F., Divita, G., A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol. Ther. 17 (2009), 95–103, 10.1038/mt.2008.215.
74. [74] Eiríksdóttir, E., Konate, K., Langel, Ü., Divita, G., Deshayes, S., Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim. Biophys. Acta Biomembr. 1798 (2010), 1119–1128, 10.1016/j.bbamem.2010.03.005.
75. [75] Kim, Y.-W., Grossmann, T.N., Verdine, G.L., Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis. Nat. Protoc. 6 (2011), 761–771, 10.1038/nprot.2011.324.
76. [76] Lehto, T., Abes, R., Oskolkov, N., Suhorutsenko, J., Copolovici, D.M., Mager, I., Viola, J.R., Simonson, O.E., Ezzat, K., Guterstam, P., Eriste, E., Smith, C.I., Lebleu, B., Samir El, A., Langel, U., Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J. Control. Release 141 (2010), 42–51, 10.1016/j.jconrel.2009.08.028.
77. [77] Sato, Y., Nakamura, T., Yamada, Y., Akita, H., Harashima, H., Chapter six – multifunctional enveloped nanodevices (MENDs). Huang, Leaf, Liu, Dexi, Wagner, Ernst, (eds.) Adv. Genet., 2014, Academic Press, 139–204 http://www.sciencedirect.com/science/article/pii/B9780128001486000067 (accessed February 23, 2016).
78. [78] Mäe, M., El Andaloussi, S., Lundin, P., Oskolkov, N., Johansson, H.J., Guterstam, P., Langel, U., A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J. Control. Release Off. J. Control. Release Soc. 134 (2009), 221–227, 10.1016/j.jconrel.2008.11.025.
79. [79] Lehto, T., Simonson, O.E., Mäger, I., Ezzat, K., Sork, H., Copolovici, D.-M., Viola, J.R., Zaghloul, E.M., Lundin, P., Moreno, P.M., Mäe, M., Oskolkov, N., Suhorutšenko, J., Smith, C.E., Andaloussi, S.E., A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol. Ther. 19 (2011), 1457–1467, 10.1038/mt.2011.10.
80. [80] Andaloussi, S.E., Lehto, T., Mager, I., Rosenthal-Aizman, K., Oprea, I., Simonson, O.E., Sork, H., Ezzat, K., Copolovici, D.M., Kurrikoff, K., Viola, J.R., Zaghloul, E.M., Sillard, R., Johansson, H.J., Said Hassane, F., Guterstam, P., Suhorutsenko, J., Moreno, P.M., Oskolkov, N., Halldin, J., Tedebark, U., Metspalu, A., Lebleu, B., Lehtio, J., Smith, C.I., Langel, U., Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 39 (2011), 3972–3987, 10.1093/nar/gkq1299.
81. [81] Ezzat, K., Andaloussi, S.E., Zaghloul, E.M., Lehto, T., Lindberg, S., Moreno, P.M., Viola, J.R., Magdy, T., Abdo, R., Guterstam, P., Sillard, R., Hammond, S.M., Wood, M.J., Arzumanov, A.A., Gait, M.J., Smith, C.I., Hallbrink, M., Langel, U., PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res. 39 (2011), 5284–5298, 10.1093/nar/gkr072.
82. [82] Ezzat, K., Zaghloul, E.M., El Andaloussi, S., Lehto, T., El-Sayed, R., Magdy, T., Smith, C.I., Langel, U., Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. J. Control. Release 162 (2012), 1–8, 10.1016/j.jconrel.2012.06.006.
83. [83] Veiman, K.-L., Mäger, I., Ezzat, K., Margus, H., Lehto, T., Langel, K., Kurrikoff, K., Arukuusk, P., Suhorutšenko, J., Padari, K., Pooga, M., Lehto, T., Langel, Ü., PepFect14 peptide vector for efficient gene delivery in cell cultures. Mol. Pharm. 10 (2013), 199–210, 10.1021/mp3003557.
84. [84] Järver, P., Zaghloul, E.M., Arzumanov, A.A., Saleh, A.F., McClorey, G., Hammond, S.M., Hällbrink, M., Langel, Ü., Smith, C.I.E., Wood, M.J.A., Gait, M.J., Andaloussi, S.E.L., Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides. Nucleic Acid Ther. 25 (2015), 65–77, 10.1089/nat.2014.0511.
85. [85] Eguchi, A., Meade, B.R., Chang, Y.C., Fredrickson, C.T., Willert, K., Puri, N., Dowdy, S.F., Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol. 27 (2009), 567–571, 10.1038/nbt.1541.
86. [86] Michiue, H., Eguchi, A., Scadeng, M., Dowdy, S.F., Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol. Ther. 8 (2009), 2306–2313.
87. [87] Morris, M.C., Gros, E., Aldrian-Herrada, G., Choob, M., Archdeacon, J., Heitz, F., Divita, G., A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res., 35, 2007, e49, 10.1093/nar/gkm053.
88. [88] Kumar, P., Wu, H., McBride, J.L., Jung, K.-E., Hee Kim, M., Davidson, B.L., Kyung Lee, S., Shankar, P., Manjunath, N., Transvascular delivery of small interfering RNA to the central nervous system. Nature 448 (2007), 39–43, 10.1038/nature05901.
89. [89] Kumar, P., Ban, H.-S., Kim, S.-S., Wu, H., Pearson, T., Greiner, D.L., Laouar, A., Yao, J., Haridas, V., Habiro, K., Yang, Y.-G., Jeong, J.-H., Lee, K.-Y., Kim, Y.-H., Kim, S.W., Peipp, M., Fey, G.H., Manjunath, N., Shultz, L.D., Lee, S.-K., Shankar, P., T Cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134 (2008), 577–586, 10.1016/j.cell.2008.06.034.
90. [90] Ren, Y., Cheung, H.W., von Maltzhan, G., Agrawal, A., Cowley, G.S., Weir, B.A., Boehm, J.S., Tamayo, P., Karst, A.M., Liu, J.F., Hirsch, M.S., Mesirov, J.P., Drapkin, R., Root, D.E., Lo, J., Fogal, V., Ruoslahti, E., Hahn, W.C., Bhatia, S.N., Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci. Transl. Med., 4, 2012, 147ra112, 10.1126/scitranslmed.3003778.
91. [91] Veiman, K.-L., Künnapuu, K., Lehto, T., Kiisholts, K., Pärn, K., Langel, Ü., Kurrikoff, K., PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. J. Control. Release 209 (2015), 238–247, 10.1016/j.jconrel.2015.04.038.
92. [92] Vivès, E., Brodin, P., Lebleu, B., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997), 16010–16017.
93. [93] Derossi, D., Joliot, A.H., Chassaing, G., Prochiantz, A., The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (1994), 10444–10450.
94. [94] Derossi, D., Calvet, S., Trembleau, A., Brunissen, A., Chassaing, G., Prochiantz, A., Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271 (1996), 18188–18193.
95. [95] Oren, Z., Shai, Y., Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47 (1998), 451–463, 10.1002/(SICI)1097-0282(1998)47:6<451::AID-BIP4>3.0.CO;2-F.
96. [96] Splith, K., Neundorf, I., Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur. Biophys. J. EBJ 40 (2011), 387–397, 10.1007/s00249-011-0682-7.
97. [97] Henriques, S.T., Melo, M.N., Castanho, M.A.R.B., Cell-penetrating peptides and antimicrobial peptides: how different are they?. Biochem. J. 399 (2006), 1–7, 10.1042/BJ20061100.
98. [98] Richard, J.P., Melikov, K., Vives, E., Ramos, C., Verbeure, B., Gait, M.J., Chernomordik, L.V., Lebleu, B., Cell-penetrating peptides. a reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278 (2003), 585–590, 10.1074/jbc.M209548200.
99. [99] Khalil, I.A., Futaki, S., Niwa, M., Baba, Y., Kaji, N., Kamiya, H., Harashima, H., Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther. 11 (2004), 636–644, 10.1038/sj.gt.3302128.
100. [100] Lundberg, P., El-Andaloussi, S., Sütlü, T., Johansson, H., Langel, U., Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 21 (2007), 2664–2671, 10.1096/fj.06-6502com.
101. [101] El-Sayed, A., Masuda, T., Khalil, I., Akita, H., Harashima, H., Enhanced gene expression by a novel stearylated INF7 peptide derivative through fusion independent endosomal escape. J. Control. Release Off. J. Control. Release Soc. 138 (2009), 160–167, 10.1016/j.jconrel.2009.05.018.
102. [102] Palm-Apergi, C., Lorents, A., Padari, K., Pooga, M., Hällbrink, M., The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 23 (2009), 214–223, 10.1096/fj.08-110254.
103. [103] Verdurmen, W.P.R., Thanos, M., Ruttekolk, I.R., Gulbins, E., Brock, R., Cationic cell-penetrating peptides induce ceramide formation via acid sphingomyelinase: implications for uptake. J. Control. Release Off. J. Control. Release Soc. 147 (2010), 171–179, 10.1016/j.jconrel.2010.06.030.
104. [104] Tyagi, M., Rusnati, M., Presta, M., Giacca, M., Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276 (2001), 3254–3261, 10.1074/jbc.M006701200.
105. [105] Mai, J.C., Shen, H., Watkins, S.C., Cheng, T., Robbins, P.D., Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 277 (2002), 30208–30218, 10.1074/jbc.M204202200.
106. [106] Belting, M., Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 28 (2003), 145–151, 10.1016/S0968-0004(03)00031-8.
107. [107] Poon, G.M.K., Gariépy, J., Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. Biochem. Soc. Trans. 35 (2007), 788–793, 10.1042/BST0350788.
108. [108] Ezzat, K., Helmfors, H., Tudoran, O., Juks, C., Lindberg, S., Padari, K., El-Andaloussi, S., Pooga, M., Langel, U., Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 26 (2012), 1172–1180, 10.1096/fj.11-191536.
109. [109] Domingues, M.M., Santiago, P.S., Castanho, M.A.R.B., Santos, N.C., What can light scattering spectroscopy do for membrane-active peptide studies?. J. Pept. Sci. Off. Publ. Eur. Pept. Soc. 14 (2008), 394–400, 10.1002/psc.1007.
110. [110] Canton, J., Neculai, D., Grinstein, S., Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol. 13 (2013), 621–634, 10.1038/nri3515.
111. [111] Liu, Y., Jones, M., Hingtgen, C.M., Bu, G., Laribee, N., Tanzi, R.E., Moir, R.D., Nath, A., He, J.J., Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat. Med. 6 (2000), 1380–1387, 10.1038/82199.
112. [112] Kondo, E., Saito, K., Tashiro, Y., Kamide, K., Uno, S., Furuya, T., Mashita, M., Nakajima, K., Tsumuraya, T., Kobayashi, N., Nishibori, M., Tanimoto, M., Matsushita, M., Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nat. Commun., 3, 2012, 951, 10.1038/ncomms1952.
113. [113] Lindberg, S., Regberg, J., Eriksson, J., Helmfors, H., Muñoz-Alarcón, A., Srimanee, A., Figueroa, R.A., Hallberg, E., Ezzat, K., Langel, Ü., A convergent uptake route for peptide- and polymer-based nucleotide delivery systems. J. Control. Release 206 (2015), 58–66, 10.1016/j.jconrel.2015.03.009.
114. [114] Srimanee, A., Regberg, J., Hällbrink, M., Vajragupta, O., Langel, Ü., Role of scavenger receptors in peptide-based delivery of plasmid DNA across a blood–brain barrier model. Int. J. Pharm. 500 (2016), 128–135, 10.1016/j.ijpharm.2016.01.014.
115. [115] Arukuusk, P., Pärnaste, L., Margus, H., Eriksson, N.K.J., Vasconcelos, L., Padari, K., Pooga, M., Langel, U., Differential endosomal pathways for radically modified peptide vectors. Bioconjug. Chem. 24 (2013), 1721–1732, 10.1021/bc4002757.
116. [116] Kohno, M., Horibe, T., Ohara, K., Ito, S., Kawakami, K., The membrane-lytic peptides K8 L9 and melittin enter cancer cells via receptor endocytosis following subcytotoxic exposure. Chem. Biol. 21 (2014), 1522–1532, 10.1016/j.chembiol.2014.09.008.
117. [117] Ezzat, K., Aoki, Y., Koo, T., McClorey, G., Benner, L., Coenen-Stass, A., O'Donovan, L., Lehto, T., Garcia-Guerra, A., Nordin, J., Saleh, A.F., Behlke, M., Morris, J., Goyenvalle, A., Dugovic, B., Leumann, C., Gordon, S., Gait, M.J., El-Andaloussi, S., Wood, M.J., Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides. Nano Lett. 15 (2015), 4364–4373, 10.1021/acs.nanolett.5b00490.
118. [118] Valero, J., Shiraishi, T., de Mendoza, J., Nielsen, P.E., Cellular antisense activity of PNA-Oligo(bicycloguanidinium) conjugates forming self-assembled nanoaggregates. Chembiochem Eur. J. Chem. Biol. 16 (2015), 1593–1600, 10.1002/cbic.201500172.
119. [119] Gao, H., Shi, W., Freund, L.B., Mechanics of receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 9469–9474, 10.1073/pnas.0503879102.
120. [120] Shi, W., Wang, J., Fan, X., Gao, H., Size and shape effects on diffusion and absorption of colloidal particles near a partially absorbing sphere: implications for uptake of nanoparticles in animal cells. Phys. Rev. E Stat. Nonlinear Soft Matter Phys., 78, 2008, 061914, 10.1103/PhysRevE.78.061914.
121. [121] Mano, M., Teodósio, C., Paiva, A., Simões, S., Pedroso de Lima, M.C., On the mechanisms of the internalization of S4(13)-PV cell-penetrating peptide. Biochem. J. 390 (2005), 603–612, 10.1042/BJ20050577.
122. [122] Padari, K., Koppel, K., Lorents, A., Hällbrink, M., Mano, M., Pedroso de Lima, M.C., Pooga, M., S4(13)-PV cell-penetrating peptide forms nanoparticle-like structures to gain entry into cells. Bioconjug. Chem. 21 (2010), 774–783, 10.1021/bc900577e.
123. [123] Pooga, M., Soomets, U., Hällbrink, M., Valkna, A., Saar, K., Rezaei, K., Kahl, U., Hao, J.X., Xu, X.J., Wiesenfeld-Hallin, Z., Hökfelt, T., Bartfai, T., Langel, U., Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16 (1998), 857–861, 10.1038/nbt0998-857.